Battle Motors Picks T-Mobile to Connect New RevolutionOS™ EV Software for Trucks
9.5.2022 16:19:00 EEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) announced that Battle Motors has selected the Un-carrier as the preferred provider of IoT connectivity and management for thousands of new Battle Motors battery electric trucks rolling off the Ohio-based production line. And these trucks are getting smarter, thanks to Battle Motors' all new factory installed RevolutionOS™ EV software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005589/en/
Battle Motors Picks T‑Mobile to Connect New RevolutionOS™ EV Software for Trucks. IoT connectivity and management powers heavy‑duty technology to electrify the commercial truck industry. (Graphic: Business Wire)
Like consumer automotive, the commercial truck industry is moving swiftly to embrace EV technology — and Battle Motors is no exception. Their RevolutionOS™, powered by T-Mobile's nationwide network, delivers actionable data and information to drivers and fleet managers that they can use to enhance efficiency, safety, and security. As part of this long-term agreement, T-Mobile for Business will deliver 4G LTE connectivity to Battle Motors trucks for near real-time sharing of battery range and usage information, historic and near real-time location and trip data, timely preventative maintenance warnings, over-the-air software, and firmware updates — as well as the truck's full bill of materials, such as VIN-specific information, parts, and manuals.
Every new Battle Motors class seven and class eight "heavy-duty" EV truck — like the ones that haul garbage, dirt, and freight — will come with a factory installed, ruggedized digital instrument cluster that runs RevolutionOS™. And thanks to the power and reliability of T-Mobile's nationwide network, Battle Motors’ RevolutionOS™ will let customers view and update critical information directly from the truck, or remotely from a desktop computer or mobile device, just by scanning a QR code!
Additionally, T-Mobile Control Center will give Battle Motors the ability to view and manage the connectivity of their trucks. With the automation and provisioning capabilities of T-Mobile’s IoT platform, Battle Motors can easily accelerate deployment of their growing line of trucks. Battle Motors will have near real-time visibility to all their commercial trucks with the ability to monitor network conditions and device behavior with T-Mobile Control Center.
In the near future, Battle Motors expects to leverage the Un-carrier's 5G network to meet industrial-sized challenges for years to come as their trucks’ capabilities advance and the demands on connectivity increase. T-Mobile is poised to push IoT to its full potential and catapult adoption — paving the way for new electric vehicle applications that rely on low-latency, high-speed data, and real-time location and proximity-based services.
“Our primary focus has been on driving technology and innovation that gives our customers value and peace-of-mind when it comes to maintenance, efficiency, safety and compliance,” says Battle Motors CSO, Paul Marsolan. “Together with T-Mobile, we’re able to merge analytics and operations to put rich, real-time decision-making data to work for our customers.”
“While we continue to grow our business market share, it energizes us to work with forward thinking companies that demonstrate leadership in areas like sustainable commercial transportation,” said Callie Field, President, T-Mobile Business Group. “Reliable connectivity, management and support is central to Battle Motors’ mission, and we’re honored that they entrusted their trucks and their customers to T-Mobile for Business.”
For more information about IoT from T-Mobile for Business, visit www.t-mobile.com/business/solutions/iot.
To find out more about Battle Motors, go to www.battlemotors.com.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.
About Battle Motors
Battle Motors, a leader in the development of electric vehicle (EV) technology, acquired commercial vehicle Original Equipment Manufacturer (OEM), Crane Carrier Company, LLC (CCC) in 2021. Battle Motors is the leader in the vocational truck industry, providing work-ready diesel, clean natural gas (CNG), and now EV chassis designed and manufactured in North America for the refuse and recycling markets. Battle Motor’s durable, dependable trucks are built to excel in a multitude of applications that now include middle-mile and last-mile delivery. CCC has been manufacturing commercial vehicles for 75 years and is based in New Philadelphia, Ohio. For more information please visit: https://www.battlemotors.com and follow us @BattleMotors
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005589/en/
Contact information
Media Contacts
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
Media Contact for Battle Motors | RevolutionOS
Jennifer Gross
Jennifer@Battlemotors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom